The AANS/CNS Drugs and Devices Committee is actively engaged with the Food and Drug Administration (FDA) and other scientific, governmental, clinical and industry representatives to provide neurosurgical expertise on drugs, devices and biologics used to treat patients and to foster innovation and patient safety. These activities include recommending neurosurgeon experts to serve on the FDA Advisory panels, providing input on FDA Guidance Documents and testimony at panel meetings, as appropriate. In addition, organized neurosurgery is an official partner with the FDA's Network of Experts program to provide rapid clinical assistance to FDA reviewers. The AANS and CNS continue to advocate policies that will decrease the regulatory burden for medical-device innovation and ensure patient access to new and improved medical technology.
Letters
RE: Support for the “Medical Product Communications Act of 2017” (H.R. 1703) Dear Congressman Griffith: The Alliance of Specialty Medicine (the “Alliance”) represents more than 100,000 specialty physicians. TheAlliance is […]
Article
Published: April 26, 2017
Introduction to FDA’sDivision of Neurological andPhysical Medicine DevicesAANS Abbreviated Slide DeckComing SoonAANS FDA Session 2018 … Read full article here
Article
Published: February 24, 2017
Perspective of a Neurosurgeon who treats Stroke Adnan H. Siddiqui, MD, PhDProfessor & Vice-Chairman Department of NeurosurgeryDirector Neurosurgical Stroke Service, Kaleida HealthChief Medical Officer, Jacobs Institute Presenting endorsed statement fromAmerican […]
Article
Published: February 10, 2017
AANS and CNS Statement on the Confirmation of Rep. Tom Price to Lead HHSNeurosurgeons Commend Senate for Approving Dr. Price’s Nomination as Nation’s Top Health Official Washington, DC—The American Association […]
Letters
Published: December 1, 2016
RE: 21st Century Cures Act Dear Majority Leader McConnell and Minority Leader Reid: The undersigned members of the Physician Clinical Registry Coalition strongly support theprovisions of the 21st Century Cures […]
Article
Published: November 9, 2016
Statementof theAmerican Association of Neurological SurgeonsCongress of Neurological Surgeonsbefore theFood and Drugs AdministrationPublic Hearingon the Subject ofManufacturer Communications ofPhysician-Directed Uses of Approved Medical ProductsNovember 9, 2016 My name is William […]
Letters
Published: August 11, 2016
Dear Speaker Ryan, On behalf of the undersigned medical specialty organizations, we applaud you for yourcommitment to move a compromise 21st Century Cures bill in the fall. As Senate MajorityLeader […]
Letters
To the Members of the United States Senate and the United States House of Representatives: The undersigned organizations representing health care providers write to express our appreciation forthe bipartisan, bicameral […]
Letters
Dear Dr. Barrasso: On behalf of the undersigned organizations, we are writing to express our strong support for S. 2978, the“Protect Continuing Physician Education and Patient Care Act,” which would […]
Article
Published: October 19, 2015
Overview On October 6, 2015, the Centers for Medicare and Medicaid Services (CMS) released its final rule, Medicare andMedicaid Programs; Electronic Health Record Incentive Program—Stage 3 and Modifications to Meaningful […]
Letters
Dear Acting Commissioner Ostroff, We are writing to express support for addressing barriers to communication that exist betweenphysicians and drug and device manufacturers. To enhance patient care, physicians must haveunrestricted […]
